Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
Dybowska D, Zarębska-Michaluk D, Rzymski P, Berak H, Lorenc B, Sitko M, Dybowski M, Mazur W, Tudrujek-Zdunek M, Janocha-Litwin J, Janczewska E, Klapaczyński J, Parfieniuk-Kowerda A, Piekarska A, Sobala-Szczygieł B, Dobrowolska K, Pawłowska M, Flisiak R. Dybowska D, et al. World J Gastroenterol. 2023 Jul 7;29(25):4085-4098. doi: 10.3748/wjg.v29.i25.4085. World J Gastroenterol. 2023. PMID: 37476581 Free PMC article.
[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].
Juszczyk J, Baka-Cwierz B, Beniowski M, Berak H, Bolewska B, Boroń-Kaczmarska A, Cianciara J, Cieśla A, Dziambor A, Gasiorowski J, Gietka A, Gliwińska E, Gładysz A, Gonciarz Z, Halota W, Horban A, Inglot M, Janas-Skulina U, Janczewska-Kazek E, Jaskowska J, Jurczyk K, Knysz B, Kryczka W, Kuydowicz J, Lakomy EA, Logiewa-Bazger B, Lyczak A, Mach T, Mazur W, Michalska Z, Modrzewska R, Nazzal K, Pabjan P, Piekarska A, Piszko P, Sikorska K, Szamotulska K, Sliwińska M, Swietek K, Tomasiewicz K, Topczewska-Staubach E, Trocha H, Wasilewski M, Wawrzynowicz-Syczewska M, Wrodycki W, Zarebska-Michaluk D, Zejc-Bajsarowicz M. Juszczyk J, et al. Przegl Epidemiol. 2005;59(3):651-60. Przegl Epidemiol. 2005. PMID: 16433307 Clinical Trial. Polish.
Distribution of HCV genotypes in Poland.
Panasiuk A, Flisiak R, Mozer-Lisewska I, Adamek A, Tyczyno M, Halota W, Pawłowska M, Stańczak J, Berak H, Wawrzynowicz-Syczewska M, Boroń-Kaczmarska A, Łapiński TW, Grzeszczuk A, Piekarska A, Tomasiewicz K, Jabłkowski M, Kryczka W, Zarebska-Michaluk D, Stepień P, Garlicki AM, Kozłowska J, Wiercińska-Drapało A, Zasik E, Mazur W, Dobracka B, Dobracki W, Simon K, Ryzko J, Pawłowska J, Dzierzanowska-Fangrat K, Januszkiewicz-Lewandowska D, Szenborn L, Zaleska I, Rokitka M, Strawińska E, Balinowska K, Smiatacz T, Stalke P, Sikorska K, Lakomy A, Zdrojewski M, Lachowicz A. Panasiuk A, et al. Przegl Epidemiol. 2013;67(1):11-6, 99-103. Przegl Epidemiol. 2013. PMID: 23745369 Free article. English, Polish.
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W. Janczewska E, et al. Medicine (Baltimore). 2015 Sep;94(38):e1411. doi: 10.1097/MD.0000000000001411. Medicine (Baltimore). 2015. PMID: 26402801 Free PMC article.
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Jacobson I, et al. World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418. World J Gastroenterol. 2016. PMID: 27022224 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska K, Piekarska A, Tronina O, Madej G, Garlicki A, Lucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski M, Horban A, Knysz B, Tudrujek M, Halota W, Simon K. Flisiak R, et al. Aliment Pharmacol Ther. 2016 Nov;44(9):946-956. doi: 10.1111/apt.13790. Epub 2016 Sep 9. Aliment Pharmacol Ther. 2016. PMID: 27611776 Free article. Clinical Trial.
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Flisiak R, et al. Adv Med Sci. 2017 Sep;62(2):387-392. doi: 10.1016/j.advms.2017.04.004. Epub 2017 May 26. Adv Med Sci. 2017. PMID: 28554119
136 results